News

The company’s drug pipeline also includes an IND-ready therapeutic candidate for Alzheimer’s disease. These two candidates are based on extensive clinical and/or preclinical R&D originally conducted by Dong-A

Loxo Oncology is engaged in the development and commercialization of highly selective drug candidates for patients with genomically defined cancers. The company is developing targeted drugs that are

PCI will add expanded Biotech clinical and commercial packaging and release testing capability at its Center of Excellence in Philadelphia, as well as expanded Cold Chain capacity at

Catalent will use the investment to enhance drug substance manufacturing capacity and drug product fill/finish capacity at its biologics manufacturing sites in Madison of Wisconsin and Bloomington of

CytoReason will receive from Pfizer payments potentially equaling up to low double digit millions of US$ for technology access fees, research support and certain success-based payments. CytoReason’s proprietary

As per the agreement, US-based Gilead will buy worldwide rights, with the exception of South Korea, to develop and commercialize novel small molecules against two undisclosed targets. In

The collaboration will combine Genentech’s global cancer immunotherapy research and development leadership with Adaptive’s proprietary T-cell receptor (TCR) discovery and immune profiling platform (TruTCR) to accelerate a transformational

BioNTech has expanded its research collaboration with Sanofi formed in late 2015 to advance the development of mRNA-based cancer immunotherapies. Simultaneously, BioNTech has signed an agreement with Sanofi

The collaboration, established in October 2017, aims to discover and develop novel GalXC RNAi therapeutics for the treatment of chronic liver diseases, with an initial focus on nonalcoholic